Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic
- 13 October 2022
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 270 (2) , 595-600
Abstract
Background Many patients treated with Natalizumab experience wearing-off symptoms (WoS) towards the end of the administration cycle. During the pandemic we advised and asked patients undergoing treatment with Natalizumab if they wanted to be shifted from a standard interval dosing (StID of 4 weeks) to an extended interval dosing (ExID of 5–6 weeks), regardless of their JCV index. Our main objective was to study prevalence and incidence of WoS when ExID was adopted. Methods We enrolled 86 patients, from May 2020 to January 2021, evaluated at baseline and during a 6 months follow-up with a survey focused on WoS, Fatigue Severity Scale (FSS), Expanded Disability Status Scale (EDSS) and MRI. Results Among the 86 patients, 32 (37.2%) reported WoS. Most common one was fatigue (93.7%). Mean EDSS was higher in the group reporting WoS (3.8 WoS vs 3.1 non-WoS, p < 0.05). Sphincterial function was the EDSS item that significantly differed between the WoS group and the non-WoS group (1.4 WoS vs 0.6 non-WoS, p < 0.001). WoS correlate with the FSS scale (p < 0.001). Conclusion Adopting an extended interval dosing does not result in significantly different occurrence of WoS between the ExID and the StID populations, in our cohort of patients. Interestingly, there is a strong correlation between WoS and a higher EDSS and FSS. Safety and efficacy of Natalizumab with ExID are relatively preserved in our study.Keywords
This publication has 28 references indexed in Scilit:
- New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studiesJournal of Neuroinflammation, 2016
- Extended interval dosing of natalizumab in multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2016
- MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patientsNature Reviews Neurology, 2015
- Body weight-based natalizumab treatment in adult patients with multiple sclerosisJournal of Neurology, 2015
- Multiple Sclerosis Symptom Recrudescence at the End of the Natalizumab Dosing CycleInternational Journal of MS Care, 2014
- Extended interval dosing of natalizumab: a two-center, 7-year experienceTherapeutic Advances in Neurological Disorders, 2014
- Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte functionNeurology, 2009
- Natalizumab plus Interferon Beta-1a for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MSExpert Review of Neurotherapeutics, 2004
- Fatigue in multiple sclerosis and its relationship to depression and neurologic disabilityMultiple Sclerosis Journal, 2000